In the same way, the recent advances about the pivotal role of IL-1 in TRAPS pathogenesis as well as the excellent results observed in clinical trials have increasingly enhanced the use of IL-1 antagonists at the expense of the anti-TNF-α agents (11, 19–22). The gene discussed is IL1B; the disease is TNF receptor 1-associated periodic fever syndrome.